International journal of nanomedicine · 2025
Tetrahedral Framework Nucleic Acids Inhibit Oxidative Stress and Cardiomyocyte Apoptosis in Doxorubicin-Induced Cardiotoxicity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pan Haizhou, Ye Qianxi, Li Yifan, Ma Liang, Ni Yiming
Аннотация
BACKGROUND: Doxorubicin-induced cardiotoxicity (DIC) is a major clinical limitation of doxorubicin therapy, driven by mitochondrial dysfunction and apoptosis. Tetrahedral framework nucleic acids (tFNAs), as novel 3D DNA nanostructures, exhibit antioxidative and anti-apoptotic properties, suggesting therapeutic potential for DIC.
METHODS: The therapeutic efficacy of tFNAs was evaluated through in vivo (mouse model) and in vitro (cardiac cell lines) experiments. Apoptotic pathways were analyzed via AKT/p53 signaling inhibition assays, while cardiac function was assessed by histological examination and biochemical analysis.
RESULTS: In vitro results demonstrated that tFNAs significantly attenuated DIC by suppressing AKT/p53-mediated apoptosis. In vivo studies confirmed functional improvement in cardiac tissue, validated by reduced biomarkers of cardiotoxicity and enhanced histological integrity.
CONCLUSION: tFNAs effectively mitigated DIC pathogenesis through dual mechanisms of mitochondrial protection and apoptosis inhibition. These findings position tFNAs as a promising therapeutic strategy for clinical DIC management, warranting further translational studies.
METHODS: The therapeutic efficacy of tFNAs was evaluated through in vivo (mouse model) and in vitro (cardiac cell lines) experiments. Apoptotic pathways were analyzed via AKT/p53 signaling inhibition assays, while cardiac function was assessed by histological examination and biochemical analysis.
RESULTS: In vitro results demonstrated that tFNAs significantly attenuated DIC by suppressing AKT/p53-mediated apoptosis. In vivo studies confirmed functional improvement in cardiac tissue, validated by reduced biomarkers of cardiotoxicity and enhanced histological integrity.
CONCLUSION: tFNAs effectively mitigated DIC pathogenesis through dual mechanisms of mitochondrial protection and apoptosis inhibition. These findings position tFNAs as a promising therapeutic strategy for clinical DIC management, warranting further translational studies.